BR112013029334A2 - método de produção de megacariócitos poliploidizados, composição de células sanguíneas, método de produção de uma plaqueta, plaqueta e produto de sangue - Google Patents

método de produção de megacariócitos poliploidizados, composição de células sanguíneas, método de produção de uma plaqueta, plaqueta e produto de sangue

Info

Publication number
BR112013029334A2
BR112013029334A2 BR112013029334-9A BR112013029334A BR112013029334A2 BR 112013029334 A2 BR112013029334 A2 BR 112013029334A2 BR 112013029334 A BR112013029334 A BR 112013029334A BR 112013029334 A2 BR112013029334 A2 BR 112013029334A2
Authority
BR
Brazil
Prior art keywords
platelet
production method
megac
pli
cell composition
Prior art date
Application number
BR112013029334-9A
Other languages
English (en)
Other versions
BR112013029334B1 (pt
Inventor
Nakauchi Hiromitsu
Eto Koji
Takayama Naoya
Nakamura Sou
Original Assignee
The University Of Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Tokyo filed Critical The University Of Tokyo
Publication of BR112013029334A2 publication Critical patent/BR112013029334A2/pt
Publication of BR112013029334B1 publication Critical patent/BR112013029334B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

mé todo de produção de megacari óci tos poli ploi di zados, composi ção de cé lulas sanguíneas, mé todo de produção de uma plaqueta, plaqueta e produto de sangue. a pr es ent e i nv ençã o r ef er e- s e à um mét odo de pr omov er a pol i pl oi di z açã o de megac ar i óc i t os e, por t ant o, pr oduçã o de megac ar i óc i t os al t ament e pol i pl oi di z ados , um mét odo de pr oduçã o ef i c i ent e de pl aquet as a par t i r de megac ar i óc i t os ' pol i pl oi di z ados e s i mi l ar es . a pr es ent e i nv ençã o f or nec e um mét odo de pr oduçã o de megac ar i óc i t os pol i pl oi di z ados c ompr eendendo uma et apa de f or çar a ex pr es s ã o de um genes upr es s or de apopt os e em megac ar i óc i t os ant es da pol i pl oi di z açã o e o c ul t i v o das c él ul as r es ul t ant es .
BR112013029334-9A 2011-05-13 2012-05-11 Método de produção de megacariócitos poliploidizados e método de produção de plaquetas BR112013029334B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011108253 2011-05-13
JP2011-108253 2011-05-13
PCT/JP2012/062217 WO2012157586A1 (ja) 2011-05-13 2012-05-11 多核化巨核球細胞、及び血小板の製造方法

Publications (2)

Publication Number Publication Date
BR112013029334A2 true BR112013029334A2 (pt) 2019-03-12
BR112013029334B1 BR112013029334B1 (pt) 2022-01-18

Family

ID=47176904

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013029334-9A BR112013029334B1 (pt) 2011-05-13 2012-05-11 Método de produção de megacariócitos poliploidizados e método de produção de plaquetas

Country Status (14)

Country Link
US (2) US9738906B2 (pt)
EP (1) EP2708597B1 (pt)
JP (1) JP5824760B2 (pt)
KR (1) KR101572344B1 (pt)
CN (1) CN103814126B (pt)
AU (1) AU2012256880B2 (pt)
BR (1) BR112013029334B1 (pt)
CA (1) CA2836073C (pt)
DK (1) DK2708597T3 (pt)
ES (1) ES2659262T3 (pt)
IL (1) IL229382B (pt)
RU (1) RU2606764C2 (pt)
SG (1) SG195007A1 (pt)
WO (1) WO2012157586A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201210857D0 (en) 2012-06-19 2012-08-01 Cambridge Entpr Ltd Transcription factor mediated programming towards megakaryocytes
EP2934555B1 (en) 2012-12-21 2021-09-22 Astellas Institute for Regenerative Medicine Methods for production of platelets from pluripotent stem cells
US20160002599A1 (en) * 2013-02-08 2016-01-07 Kyoto University Production methods for megakaryocytes and platelets
WO2014168255A1 (ja) * 2013-04-12 2014-10-16 国立大学法人京都大学 巨核球の成熟化促進物質
JP6551963B2 (ja) * 2014-05-14 2019-07-31 国立大学法人京都大学 巨核球前駆細胞の製造方法
JP6655011B2 (ja) * 2014-06-23 2020-02-26 東亞合成株式会社 細胞の多核化を誘導するペプチドおよびその利用
KR102563564B1 (ko) * 2015-04-14 2023-08-07 고쿠리츠 다이가쿠 호진 교토 다이가쿠 체세포로의 분화 유도에 적합한 줄기 세포 클론을 제조하는 방법
AU2016278335B2 (en) * 2015-06-16 2021-10-28 Kyoto University Method for producing highly functional platelets
CA2998463A1 (en) * 2015-09-15 2017-03-23 Megakaryon Corporation Method for manufacturing platelets by rotary stirring culture method
KR102689261B1 (ko) * 2015-10-14 2024-07-30 가부시키가이샤 메가카리온 정제 혈소판의 제조 방법
RU2741871C2 (ru) * 2015-11-02 2021-01-29 Мегакарион Корпорейшн Способ получения тромбоцитов с помощью устройства для возвратно-поступательного перемешивания
EP3409774A4 (en) 2016-01-29 2019-10-23 Kyoto University SCREENING PROCESS FOR PROMOTER OF THROMBOZYTE PRODUCTION
US10941382B2 (en) * 2016-01-29 2021-03-09 Kyoto University Platelet production promoter and method of producing platelets using same
CA3029450C (en) * 2016-06-27 2021-07-13 The General Hospital Corp Dba Massachusetts General Hospital Stimulating platelet generation by activating mitochondrial biogenesis
JP7297203B2 (ja) 2017-03-06 2023-06-26 国立大学法人京都大学 血小板の製造方法
JP7153276B2 (ja) 2017-07-07 2022-10-14 国立大学法人京都大学 血小板の製造方法および製造装置、ならびに血小板の製造装置における運転条件の決定方法
JP7323126B2 (ja) 2017-09-19 2023-08-08 株式会社メガカリオン 精製血小板の製造方法、血小板製剤の製造方法、血液製剤の製造方法、血小板保存液、血小板保存剤および血小板の保存方法
WO2019059234A1 (ja) 2017-09-19 2019-03-28 株式会社メガカリオン 血小板の製造方法、血小板製剤の製造方法、および血液製剤の製造方法
KR102592176B1 (ko) 2018-01-05 2023-10-20 플레이틀렛 바이오제네시스, 인크. 거핵구 생성을 위한 조성물 및 방법
CN110373386A (zh) * 2019-07-02 2019-10-25 中国医学科学院血液病医院(中国医学科学院血液学研究所) Jak激酶抑制剂在制备促进多能干细胞诱导产生巨核细胞和血小板的产品中的用途
TW202128987A (zh) * 2019-10-17 2021-08-01 國立大學法人千葉大學 巨核細胞前驅細胞或巨核細胞之製造方法
CN110564687B (zh) * 2019-11-05 2020-04-03 诺未科技（北京）有限公司 用于扩增造血干细胞的组合物、培养基、方法和试剂盒
JP7058431B2 (ja) * 2019-12-12 2022-04-22 国立大学法人千葉大学 巨核球および血小板を含む凍結乾燥製剤
EP4063489A4 (en) * 2019-12-13 2024-02-28 Megakaryon Corporation COMPOSITION AND USE THEREOF
WO2021172583A1 (ja) * 2020-02-28 2021-09-02 大塚製薬株式会社 遺伝子改変巨核球、改変血小板及びそれらの製造方法
JP7521738B2 (ja) 2020-05-18 2024-07-24 キヤノン株式会社 目的細胞の生産方法、目的細胞による生産物の生産方法、および無血清培地
EP4238572A4 (en) 2020-10-27 2024-10-16 Univ Nagasaki OSTEOGENIC COMPOSITION AND ASSOCIATED USE
JPWO2022265117A1 (pt) 2021-06-18 2022-12-22
US20240301353A1 (en) 2021-06-30 2024-09-12 National University Corporation Chiba University Method for improving proliferative properties of common myeloid progenitor cells (cmp) or myelocytic progenitor cells
WO2024076030A1 (ko) * 2022-10-05 2024-04-11 주식회사 듀셀바이오테라퓨틱스 혈소판의 제조 방법
KR20240055673A (ko) 2022-10-18 2024-04-29 의료법인 성광의료재단 줄기세포에서 혈소판 전구세포로의 분화 유도용 배지 조성물 및 이를 이용한 분화 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA951199B (en) * 1994-02-14 1996-08-14 Kirin Brewery Protein having tpo activity
EP1149906A1 (en) * 2000-04-25 2001-10-31 Pliva, Farmaceutska, Industrija, Dionicko Drustvo Thrombopoietin receptor modulating peptide
CN1286970C (zh) * 2003-12-30 2006-11-29 上海伯瑞生物技术发展有限公司 由脐血cd34+细胞体外诱导生成巨核细胞的方法
US8058064B2 (en) 2006-10-04 2011-11-15 The University Of Tokyo Sac-like structure enclosing hematopoietic progenitor cells produced from ES cells and method for preparing blood cells
JP2009213645A (ja) * 2008-03-10 2009-09-24 Barudan Co Ltd シークインテープ供給装置
WO2009122747A1 (ja) 2008-04-01 2009-10-08 国立大学法人東京大学 ｉＰＳ細胞からの血小板の調製方法
ES2725688T3 (es) * 2009-09-15 2019-09-26 Univ Tokyo Método novedoso para la producción de células diferenciadas
AU2012231207B2 (en) * 2011-03-18 2016-06-23 New York Blood Center, Inc. Megakaryocyte and platelet production from stem cells
RU2482870C1 (ru) * 2012-02-27 2013-05-27 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Российской академии медицинских наук (ФГБУ "РОНЦ им. Н.Н. Блохина" РАМН) Средство, индуцирующее дифференцировку стволовых кроветворных клеток в тромбоциты

Also Published As

Publication number Publication date
RU2013154962A (ru) 2015-06-20
US20180016597A1 (en) 2018-01-18
CA2836073C (en) 2019-07-23
ES2659262T3 (es) 2018-03-14
IL229382B (en) 2018-02-28
JP5824760B2 (ja) 2015-12-02
EP2708597A4 (en) 2014-11-19
KR101572344B1 (ko) 2015-11-26
WO2012157586A1 (ja) 2012-11-22
RU2606764C2 (ru) 2017-01-10
JPWO2012157586A1 (ja) 2014-07-31
AU2012256880A1 (en) 2013-12-12
IL229382A0 (en) 2014-01-30
DK2708597T3 (en) 2018-02-05
EP2708597B1 (en) 2017-11-15
SG195007A1 (en) 2013-12-30
US10533185B2 (en) 2020-01-14
KR20140029488A (ko) 2014-03-10
CA2836073A1 (en) 2012-11-22
EP2708597A1 (en) 2014-03-19
BR112013029334B1 (pt) 2022-01-18
CN103814126A (zh) 2014-05-21
US9738906B2 (en) 2017-08-22
US20140127815A1 (en) 2014-05-08
AU2012256880B2 (en) 2015-09-17
CN103814126B (zh) 2017-10-24

Similar Documents

Publication Publication Date Title
BR112013029334A2 (pt) método de produção de megacariócitos poliploidizados, composição de células sanguíneas, método de produção de uma plaqueta, plaqueta e produto de sangue
BR112013022788A2 (pt) "composição farmacêutica compreendendo uma dispersão sólida de 1-(4-benzidrilpiperazin-1-il)-3,3-difenilpropan-1-ona"
BR112015011158A2 (pt) triazolopirazina
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
CR20150523A (es) Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
NI200900159A (es) Moduladores de 2-aminopirimidina del receptor de histamina h4.
BR112014027227A2 (pt) modificação alvejada de malato desidrogenase
EP4233545A3 (en) Synergistic bacterial compositions and methods of production and use thereof
BR112016003053A2 (pt) micropartículas de células tronco e mirna
BR112014018524A2 (pt) derivados de pirimido [4,5-b]indol e métodos de utilização dos mesmos na expansão de células-tronco hematopoiéticas, composição farmacêutica e kits
BR112015005048A8 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
CO6650354A2 (es) Composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3[6-(4-metil-piperazin-1-il)-1h-bendimidazol-2-il]-1h-quinolin-2-ona
CO6670575A2 (es) Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
BR112012019190A2 (pt) composições de cuidado oral.
EA201891115A1 (ru) Новая фармацевтическая композиция, содержащая частицы, содержащие комплекс двухнитевого полирибонуклеотида и полиалкиленимина
BR112013026965A2 (pt) método para inibir micro-organismos prejudiciais e composição formadora de barreira para os mesmos
WO2014066916A3 (en) Compositions and methods for safe treatment of rhinitis
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
IN2014MN02056A (pt)
BR112015013783A2 (pt) quitina ou seus derivados para a prevenção e / ou tratamento de parasitoses
BR112016015190A8 (pt) Composição farmacêutica livre de antioxidante e método de preparação da mesma
WO2012129077A3 (en) Peptides for suppressing inflammation

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/05/2012, OBSERVADAS AS CONDICOES LEGAIS.